Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02628223 · ClinicalTrials.gov registry record · NA
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
A NA study, sponsored by Temple University.
- Completed
- Registry status
- NA
- Development phase
- 76
- Enrollment target
NCT02628223 is a NA study that has completed, run by Temple University. The registered enrollment target is 76 participants.
The verdict
NCT02628223, a NA study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
Study Summary
Selective laser trabeculoplasty (SLT) is a well-recognized way to lower eye pressure in treatment of glaucoma. This treatment is performed for 180 degrees or 360 degrees, and studies at academic centers have shown mixed results when comparing the success rates of 180 degrees or 360 degrees. Both protocols are now typically done by comprehensive ophthalmologists. However, there is no data that compares success rates of 180 degrees and 360 degrees in the community setting.
Interventions
- PROCEDURE Selective Laser Trabeculoplasty
- DEVICE Neodymium:Yttrium Aluminum Garnet (YAG) laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02628223
The ClinicalTrials.gov registry entry for NCT02628223 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selective Laser Trabeculoplasty is the first listed.
NCT02628223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02628223 about?
NCT02628223 is a clinical study titled "180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma". Selective laser trabeculoplasty (SLT) is a well-recognized way to lower eye pressure in treatment of glaucoma. This treatment is performed for 180 degrees or 360 degrees, and studies at academic centers have shown mixed results when comparing the success rates of 180 degrees or 360 degrees. Both pro...
What is the current status of trial NCT02628223?
This trial is currently completed. It is a NA study. The enrollment target is 76 participants. The study started on 2014-09. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02628223?
The interventions under investigation include: Selective Laser Trabeculoplasty (PROCEDURE), Neodymium:Yttrium Aluminum Garnet (YAG) laser (DEVICE).
Who is sponsoring clinical trial NCT02628223?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.